Department of Surgery, Memorial Sloan-Kettering Cancer Center , New York, NY 10065, USA.
J Palliat Med. 2011 Jul;14(7):822-8. doi: 10.1089/jpm.2010.0506. Epub 2011 May 19.
Malignant bowel obstruction (MBO), a serious problem in stage IV colorectal cancer (CRC) patients, remains poorly understood. Optimal management requires realistic assessment of treatment goals. This study's purpose is to characterize outcomes following palliative intervention for MBO in the setting of metastatic CRC.
Retrospective review of a prospective palliative database identified 141 patients undergoing surgical (OR; n = 96) or endoscopic (GI; n = 45) procedures for symptoms of MBO.
Median patient age was 58 years, median follow-up 7 months. Most (63%) had multiple sites of metastases. Computed tomography (CT) scan findings of carcinomatosis (p = 0.002), ascites (p = 0.05), and multifocal obstruction with carcinomatosis and ascites (p = 0.03) significantly predicted the need for percutaneous or open gastrostomy tube, or stoma. Procedure-associated morbidity for 81 patients with small bowel obstruction (SBO) was 37%; 7% developed an enterocutaneous fistula/anastomotic leak. Thirty-day mortality was 6%. Most (84%) patients were palliated successfully; some received additional chemotherapy (38%) or surgery (12%). Procedure-associated morbidity for 60 patients with large bowel obstruction (LBO) was 25%; 11 patients (18%) required other procedures for stent failure, with one death at 30 days. Symptom resolution was >97%. Patients with LBO had improved symptom resolution, shorter length of stay (LOS), and longer median survival than patients with SBO.
Patients with MBO and stage IV CRC were successfully palliated with GI or OR procedures. Patients with CT-identified ascites, carcinomatosis, or multifocal obstruction were least likely to benefit from OR procedures. CT plays an important role in preoperative planning. Sound clinical judgment and improved understanding are required for optimal management of MBO.
恶性肠梗阻(MBO)是晚期结直肠癌(CRC)患者的严重问题,但仍未得到充分认识。最佳治疗需要对治疗目标进行现实评估。本研究旨在描述转移性 CRC 患者中 MBO 姑息治疗后的结局。
回顾性分析前瞻性姑息治疗数据库,纳入 141 例因 MBO 症状接受手术(OR;n=96)或内镜(GI;n=45)治疗的患者。
患者中位年龄为 58 岁,中位随访时间为 7 个月。大多数(63%)有多处转移灶。CT 扫描发现癌性腹膜转移(p=0.002)、腹水(p=0.05)以及癌性腹膜转移合并腹水和多灶性梗阻(p=0.03)显著预测需要进行经皮或开放性胃造口管或造口术。81 例小肠梗阻(SBO)患者的手术相关并发症发生率为 37%;7%发生肠外瘘/吻合口漏。30 天死亡率为 6%。大多数(84%)患者得到成功姑息治疗;部分患者接受了额外的化疗(38%)或手术(12%)。60 例大肠梗阻(LBO)患者的手术相关并发症发生率为 25%;11 例(18%)因支架失败需要进行其他手术,其中 1 例患者在 30 天内死亡。症状缓解率>97%。与 SBO 患者相比,LBO 患者的症状缓解率更高、住院时间更短、中位生存时间更长。
MBO 和 IV 期 CRC 患者可通过 GI 或 OR 治疗得到成功姑息治疗。CT 检查发现腹水、癌性腹膜转移或多灶性梗阻的患者最不可能从 OR 治疗中获益。CT 在术前规划中具有重要作用。需要有良好的临床判断和对 MBO 进行优化管理的理解。